We hypothesized that systemic Aurora-A inhibition may impair MDSC function, thereby promoting anti-tumor immunity; the increased expression of IL-16 in systemic Aurora-A inhibitor-treated mice might counteract this beneficial effect. Here, IL16 is linked to neoplasm.